22.9.2026 07:30:26 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state
Oslo, 22 September 2026. Reference is made to the announcement by Thor Medical
ASA (the "Company") on 3 September 2026, regarding, among other things, the
successful completion of a private placement of new shares in the Company
raising aggregate gross proceeds of NOK 300 million (the "Private Placement")
and a separate retail offering through Nordnet Bank AB raising gross proceeds of
up to the NOK equivalent of EUR 1 million (the "Retail Offering") and a
potential subsequent offering of up to 9,400,000 new shares at a subscription
price of NOK 4.80 per share (the "Subsequent Offering").
The Company has decided not to proceed with the Subsequent Offering.
Since the announcement of the completion of the Private Placement, the
Company's shares have traded on Euronext Oslo Børs, with sufficient trading
volume, at prices close to or below the subscription price in the Private
Placement of NOK 4.80. Accordingly, any shareholders wishing to neutralize the
dilutive effect of the Private Placement have had the opportunity to purchase
shares in the Company in the market, at prices close to or below what would have
been the subscription price in the Subsequent Offering. In light of this, the
Company has resolved not to proceed with the Subsequent Offering.
Contacts
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05
724, mathias.reierth@thormedical.com - brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes.
Thor Medical supports radiopharmaceutical companies from early-stage development
to commercialization, enabling scale-up of next-generation targeted cancer
therapies. Thor Medical's product portfolio includes lead-212 (Pb-212) and its
precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on
naturally occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED.
For more information, visit https://www.thormedical.com/.
This information is published in accordance with the requirements of the
Continuing Obligations for companies listed on Euronext Oslo Børs and section
5-12 of the Norwegian Securities Trading Act.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19075541/18217/Download%20announc
ement%20as%20PDF.pdf
ikasjon.ntb.no/ir-files/17848634/19075541/18217/Download%20announc\
ement%20as%20PDF.pdf\